Home > Healthcare > Pseudomonas Aeruginosa Treatment Market

Pseudomonas Aeruginosa Treatment Market Share

Report ID: GMI10073
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Pseudomonas Aeruginosa Treatment Market Share

The competitive landscape in the pseudomonas aeruginosa treatment industry is characterized by a mix of established pharmaceutical companies and innovative biotech firms striving to develop effective therapies against this challenging pathogen. Key players such as Merck & Co., Inc., Pfizer Inc., and Novartis AG dominate the market with a range of antibiotic. The market also witnesses collaborations and partnerships among companies to leverage each other's strengths in research, development, and commercialization.

Pseudomonas Aeruginosa Treatment Market Companies

Prominent players operating in the pseudomonas aeruginosa treatment industry include:

AbbVie Inc.
AstraZeneca PLC
Bristol Myers Squibb Company
Baxter International Inc.
Lupin Pharmaceuticals Inc.
Merck & Co. Inc.
Neopharma
Novartis AG
Pfizer Inc.
Sanofi SA
Shionogi & Co., Ltd.
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Pseudomonas aeruginosa treatment industry size was USD 1.9 billion in 2023 and will grow at 5.8% CAGR between 2024 and 2032, driven by increasing incidence of infections caused by this bacterium, particularly in hospital settings.

The combination therapy segment will record USD 1.1 billion by 2032, attributed to its enhanced efficacy in combating antibiotic-resistant strains.

North America pseudomonas aeruginosa treatment industry size will achieve USD 1 billion by 2032, fueled by the advanced healthcare infrastructure and significant investment in research and development.

AbbVie Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Baxter International Inc., Lupin Pharmaceuticals Inc., Merck & Co. Inc., Neopharma, Novartis AG, Pfizer Inc., Sanofi SA, Shionogi & Co., Ltd., and Teva Pharmaceutical Industries Ltd.